Hence, in vitro and in vivo experiments showed that FXR agonists have a vital role in suppressing cancer causing oncogenes and in regulating conditions such as proteinuria, glomerular inflammation, and fibrosis, and therefore, targeting FXR for developing therapeutics is a potential area of research. The gene discussed is NR1H4; the disease is cancer.